The issuance of a patent provides Cognition Therapeutics with exclusive rights to their compositions for treating neurodegenerative diseases, which could lead to significant advancements in the field. This exclusivity can attract investor attention and potentially increase the company's valuation due to the critical need for such treatments. The patent not only strengthens their intellectual property portfolio but also positions them as key players in the neurodegenerative disease treatment market.